Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Watson Labs Inc.

Pharmaceutical intelligence for Watson Labs Inc. with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
0
Assets
1

Recent signals(1)

RegulatoryAugust 14, 2026

Watson Labs receives AP status for Metformin Hydrochloride ANDA076818

Watson Labs Inc. has received Abbreviated Approval (AP) for ANDA076818, a generic version of Metformin Hydrochloride, from the FDA. This approval confirms that Watson Labs has met the necessary regulatory standards for the product, which is positioned within the diabetes treatment market.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryAugust 14, 2026

Watson Labs receives AP status for Metformin Hydrochloride ANDA076818

Watson Labs Inc. has received Abbreviated Approval (AP) for ANDA076818, a generic version of Metformin Hydrochloride, from the FDA. This approval confirms that Watson Labs has met the necessary regulatory standards for the product, which is positioned within the diabetes treatment market.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Watson →

Therapeutic areas

Diabetes →
Oral Hypoglycemic →

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.